GURUFOCUS.COM » STOCK LIST » Technology » Software » Enfusion Inc (NYSE:ENFN) » Definitions » EV-to-EBITDA

Enfusion (Enfusion) EV-to-EBITDA : 49.19 (As of May. 16, 2024)


View and export this data going back to 2021. Start your Free Trial

What is Enfusion EV-to-EBITDA?

EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Enfusion's enterprise value is $833.7 Mil. Enfusion's EBITDA for the trailing twelve months (TTM) ended in Mar. 2024 was $16.9 Mil. Therefore, Enfusion's EV-to-EBITDA for today is 49.19.

The historical rank and industry rank for Enfusion's EV-to-EBITDA or its related term are showing as below:

ENFN' s EV-to-EBITDA Range Over the Past 10 Years
Min: -184.96   Med: 48.44   Max: 193.59
Current: 49.19

During the past 5 years, the highest EV-to-EBITDA of Enfusion was 193.59. The lowest was -184.96. And the median was 48.44.

ENFN's EV-to-EBITDA is ranked worse than
84.46% of 1853 companies
in the Software industry
Industry Median: 14.53 vs ENFN: 49.19

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-05-16), Enfusion's stock price is $9.43. Enfusion's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 was $0.030. Therefore, Enfusion's PE Ratio for today is 314.33.

The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.


Enfusion EV-to-EBITDA Historical Data

The historical data trend for Enfusion's EV-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Enfusion EV-to-EBITDA Chart

Enfusion Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-EBITDA
- - -4.97 -118.88 39.23

Enfusion Quarterly Data
Dec19 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
EV-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 64.59 49.61 41.28 39.23 49.47

Competitive Comparison of Enfusion's EV-to-EBITDA

For the Software - Application subindustry, Enfusion's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Enfusion's EV-to-EBITDA Distribution in the Software Industry

For the Software industry and Technology sector, Enfusion's EV-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Enfusion's EV-to-EBITDA falls into.



Enfusion EV-to-EBITDA Calculation

Enfusion's EV-to-EBITDA for today is calculated as:

EV-to-EBITDA=Enterprise Value (Today)/EBITDA (TTM)
=833.666/16.949
=49.19

Enfusion's current Enterprise Value is $833.7 Mil.
Enfusion's EBITDA for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $16.9 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Enfusion  (NYSE:ENFN) EV-to-EBITDA Explanation

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

Enfusion's PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=9.43/0.030
=314.33

Enfusion's share price for today is $9.43.
Enfusion's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.030.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.

Please read Which price ratio outperforms the enterprise multiple?


Enfusion EV-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Enfusion's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Enfusion (Enfusion) Business Description

Traded in Other Exchanges
N/A
Address
125 South Clark Street, Suite 750, Chicago, IL, USA, 60603
Enfusion Inc is a software-as-a-service (SaaS) provider focused on transforming the investment management industry. Its solutions are designed to eliminate technology and information barriers, empowering investment managers to make and execute better-informed investment decisions in real-time. It simplifies investment and operational workflows by unifying mission-critical systems and coalescing data into a single dataset resulting in a single source of truth.
Executives
Deirdre Somers director C/O ENFUSION, INC., 125 SOUTH CLARK STREET, SUITE 750, CHICAGO IL 60603
Bradley Herring officer: Chief Financial Officer C/O SHIFT4 PAYMENTS, INC., 2202 N. IRVING STREET, ALLENTOWN PA 16109
Oleg Movchan director, 10 percent owner C/O ENFUSION INC., 125 SOUTH CLARK ST. STE 750, CHICAGO IL 60603
Bronwen Bastone officer: Chief People Officer C/O ENFUSION, INC., 125 SOUTH CLARK STREET SUITE 750, CHICAGO IL 60603
Stephen Malherbe 10 percent owner C/O ENFUSION, INC., 125 SOUTH CLARK STREET, SUITE 750, CHICAGO IL 60603
Dan Groman officer: Chief Technology Officer C/O ENFUSION INC., 125 SOUTH CLARK STREET STE. 750, CHICAGO IL 60603
Tarek Hammoud 10 percent owner C/O ENFUSION INC., 125 SOUTH CLARK ST. STE. 750, CHICAGO IL 60603
Ftv Investment Holdings, L.p. 10 percent owner 601 CALIFORNIA STREET, FLOOR 19, SAN FRANCISCO CA 94108
Michael Spellacy director 399 PARK AVENUE, NEW YORK NY 10022
Quiet Light Securities, Llc 10 percent owner 70 WEST MADISON, SUITE 1675, CHICAGO IL 60602
Steven M. Bachert officer: Chief Revenue Officer C/O ENFUSION INC., 125 SOUTH CLARK ST., STE 750, CHIGAGO IL 60603
Lra Ventures, Llc 10 percent owner C/O ENFUSION, INC., 125 SOUTH CLARK STREET, SUITE 750, CHICAGO IL 60603
Hillhouse Investment Management, Ltd. 10 percent owner OFFICE #122, WINDWARD 3 BUILDING, REGATTA OFFICE PARK, WEST BAY ROAD, GRAND CAYMAN E9 KY1-9006
Roy Luo director 394 PACIFIC AVENUE, 2ND FLOOR, SAN FRANCISCO CA 94111
Iconiq Strategic Partners V-b, L.p. 10 percent owner 394 PACIFIC AVENUE, SECOND FLOOR, SAN FRANCISCO CA 94111

Enfusion (Enfusion) Headlines

From GuruFocus

Enfusion Announces First Quarter 2022 Earnings Release Date

By Business Wire Business Wire 04-29-2022

Enfusion Announces Resignation of Chief Financial Officer

By Business Wire Business Wire 11-28-2022

Enfusion Announces First Quarter 2023 Results

By Business Wire Business Wire 05-09-2023

Enfusion Announces Second Quarter 2023 Results

By Business Wire 08-08-2023